ClinicalTrials.gov
public full text
Public Domain
Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
The purpose of this study is to demonstrate the safety, tolerability and clinical benefit of TYSABRI® (natalizumab) in patients with moderately to severely active Crohn's disease.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease#1150274
- Predictive Factors of Clinical Response to Ustekinumab in Active Crohn's Disease#837961
- Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease#827285
- The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease#1100538
- A mathematical model to simulate the biological action of Infliximab on TNF-$$\alpha $$ in patients with Inflammatory Bowel Disease: the critical role of drug clearance#1053169
Record · ID 1101133
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive